They’re betting that with the continuous need for health care, the sector is more immune.

Biopharma VC deal value fell to $7.2 billion in Q1 2026 as capital shifted toward exits. We examine modality trends, oncology, and obesity deal flow, and what a strengthening exit environment means for 2026.

Investors are eyeing a strong M&A cycle ahead of 2030.

EMed secures Series A at a $2B valuation. But will its adherence rate hold up at scale?

The Q4 2024 Biopharma VC Trends report provides an analysis of recent VC activity and includes a market map of leading VC-backed companies in the space.

This analyst note examines the Chinese biopharma sector’s shift toward a more self-reliant, globally integrated ecosystem, leading early-stage innovation and licensing despite reduced nondomestic VC and rising geopolitical frictions.

Our 2026 Healthcare Outlook forecasts trends that will shape the healthcare PE and VC ecosystems in the upcoming year.

Founders say they’re workshopping their edge over conventional LLMs for drug development purposes.

This analyst note examines how AI is transforming biopharma by streamlining drug discovery and development, reshaping business models, and entering a pivotal stage of clinical validation.

The Q3 2025 Biopharma VC Trends report provides an analysis of recent VC activity and includes a market map of leading VC-backed companies in the space.

The Q2 2025 Biopharma VC Trends report provides an analysis of recent VC activity and includes a market map of leading VC-backed companies in the space.

This analysis provides investors and fund managers with a data-driven view of biotech VC performance and structural trends.

The Q1 2025 Biopharma Modalities VC Trends report provides an analysis of recent VC activity and includes a market map of leading VC-backed companies in the space.

The Q4 2024 Biopharma Modalities VC Trends report provides an analysis of recent VC activity and includes a market map of leading VC-backed companies in the space.

This analyst note shares insights on the conference’s central themes and examines how industry developments during the event aligned with our healthcare industry outlook for 2025.

The chemistry sector of biopharma has consistently been the vertical’s best performing segment.

Our 2025 Healthcare & Life Sciences Outlook forecasts trends that will shape the healthcare and life sciences PE and VC ecosystems in the upcoming year.

This analyst note discusses key takeaways from McDermott, Will & Emery’s Annual Life Sciences Dealmaking Symposium in November.